[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-334103-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-334103-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-oncogenic-functions-of-sparcl1-in-bladder-cancer","The oncogenic functions of SPARCL1 in bladder cancer","","Secreted protein acidic and rich in cysteine-like 1 (SPARCL1) belongs to the SPARC family of matricellular proteins, yet its roles in bladder cancer (BCa) remain insufficiently characterized. An integrated analysis linked SPARCL1 expression with multiple clinicopathological variables, followed by GO/KEGG and GSEA pathway enrichment. Correlations were assessed with immunological features including TMB, immune activation, immune checkpoint expression, TIDE scores, and chemotherapeutic sensitivity. SPARCL1 was downregulated across cancers, but elevated SPARCL1 in BCa associated with advanced stage, worse prognosis, and in vitro inhibition of proliferation, migration, and invasion; it also correlated with immune-stromal and ESTIMATE scores and immune cell markers.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-oncogenic-functions-of-sparcl1-in-bladder-cancer/334103/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-oncogenic-functions-of-sparcl1-in-bladder-cancer/334103.png","ImageObject",300,407,{"name":42,"@type":43},"Eden","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is SPARCL1 and how is it connected to bladder cancer in this study?","Question",{"text":63,"@type":64},"SPARCL1 is a secreted matricellular protein in the SPARC family. The study evaluates how SPARCL1 expression relates to bladder cancer expression patterns, clinicopathological features, immune features, and outcomes.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was SPARCL1 analyzed across bladder cancer cohorts and molecular pathways?",{"text":68,"@type":64},"The authors performed an integrated search for SPARCL1 expression patterns across clinicopathological features, then used GO enrichment, KEGG pathway enrichment, and gene set enrichment analysis (GSEA) to explore associated biological processes and pathways.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the study find about the prognostic value of SPARCL1 in bladder cancer?",{"text":72,"@type":64},"In bladder cancer, higher SPARCL1 expression was linked to more advanced histopathologic stage, higher T and N stage, and poorer prognosis in the clinical cohort. The study also supports its potential as a biomarker by connecting SPARCL1 with immune and stromal components.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},334103,1791153966,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":108,"preview_page_count":4},1374391974468,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","DOI: 10. 1111/jcmm.70196  \nOR I G I NAL ART I C L E  \nThe oncogenic functions of SPARCL1 in bladder cancer  \nChangjiu Li1 | Hui Yuan2,3 | Jun Chen2 | Kun Shang2 | Huadong He1,2   \n1Department of Urology, Affiliated Hangzhou First People's Hospital, Westlake University School of Medicine, Hangzhou, China  \n2The Fourth Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China  \n3 Department of Urology, Ninghai First Hospital, Ningbo  \nCorrespondence  \nHuadong He, Department of Urology, Affiliated Hangzhou First People's Hospital, Westlake University School of Medicine, Hangzhou, China.  \nEmail: [harry_lee99@163.com](harry_lee99@163.com)  \nFunding information  \nZhejiang Medical Science and Technology Project, Grant/Award Number: 2022507093 and 2024KY230; Hangzhou Health and Technology Project, Grant/ Award Number: A20210162 and ZD20210043  \nAbstract  \nSecreted protein, acidic and rich in cysteine-like 1 (SPARCL1) belongs to the SPARC family of matricellular proteins. However, underlying functions of SPARCL1 in bladder cancer (BCa) remain understudied. We performed an integrated search for the expression patterns of SPARCL1 in relation to various clinicopathological features of BCa. We then carried out Gene Ontology (GO) enrichment analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis, and gene set enrichment analysis (GSEA). Furthermore, we investigated the correlations between SPARCL1 and immunological features, such as tumour mutation burden (TMB), immune activation processes, immune checkpoint expression, tumour immune dysfunction and exclusion (TIDE) scores, and chemotherapeutic sensitivity in BCa. Our analysis revealed that SPARCL1 was downregulated across multiple cancers. In BCa, elevated SPARCL1 was linked with advanced histopathologic stage, higher T and N stage, and poorer prognosis in the clinical cohort. In vitro experiments demonstrated that increased SPARCL1 expression inhibited cell proliferation, migration, and invasion. Additionally, highly expressed SPARCL1 was linked to elevated immune, stromal and ESTIMATE scores, as well as an increase in naive B cells, M2 macrophages, and resting mast cells. We observed a moderate correlation between SPARCL1 expression and CD163, VSIG4 and MS4A4A, which are markers of M2 macrophages. Furthermore, SPARCL1 expression was positively related to TMB, immune activation processes, TIDE scores, immune checkpoint expression, and chemotherapeutic sensitivity in BCa. Our study highlights the potential involvement of SPARCL1 in macrophage recruitment and polarization and suggests its utility as a biomarker for prognosis in BCa.  \nK E Y WO R D S  \nbladder cancer, immune infiltration, M2 macrophage, prognosis, SPARCL1  \n1 | INTRODUCTION  \nBladder cancer (BCa) remains a significant reason of cancer-related deaths, estimated to have nearly 212,536 related deaths in 2020.1 The advent of immunotherapy has revolutionized BCa treatment, with the introduction of antibodies targeting programmed cell death protein-1 (PD-1), such as avelumab and pembrolizumab.2,3 Whereas, only a few  \npatients benefit from immunotherapy, and the current prognostic factors, including tumour mutation burden (TMB), microsatellite instability (MSI), and PD-1/PD-L1 expression, are insufficient for accurately predicting immunotherapeutic response.4,5 To address this challenge, ongoing clinical trials are exploring more effective immune checkpoint blockade (ICB) strategies, and there is a growing need to understand the tumour microenvironment and identify reliable biomarkers.  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2024 The Author(s) . Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.  \nJ Cell Mol Med. 2024;28:e70196 .  \n[https","cbCaihX4swo24wLB","https://ap.wps.com/l/cbCaihX4swo24wLB","pdf",6920252,16,"English","# Abstract\n# 1 | Introduction","[{\"question\":\"What is SPARCL1 and how is it connected to bladder cancer in this study?\",\"answer\":\"SPARCL1 is a secreted matricellular protein in the SPARC family. The study evaluates how SPARCL1 expression relates to bladder cancer expression patterns, clinicopathological features, immune features, and outcomes.\"},{\"question\":\"How was SPARCL1 analyzed across bladder cancer cohorts and molecular pathways?\",\"answer\":\"The authors performed an integrated search for SPARCL1 expression patterns across clinicopathological features, then used GO enrichment, KEGG pathway enrichment, and gene set enrichment analysis (GSEA) to explore associated biological processes and pathways.\"},{\"question\":\"What did the study find about the prognostic value of SPARCL1 in bladder cancer?\",\"answer\":\"In bladder cancer, higher SPARCL1 expression was linked to more advanced histopathologic stage, higher T and N stage, and poorer prognosis in the clinical cohort. The study also supports its potential as a biomarker by connecting SPARCL1 with immune and stromal components.\"}]","The oncogenic functions of SPARCL1 in bladder cancer | PDF",1790005272]